(DTIL) Precision BioSciences, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(DTIL) Precision BioSciences, Inc. Complete Analysis Pack
Precision BioSciences: Uncover the Strategy Behind the Model
Unlock the full strategic blueprint behind Precision BioSciences, Inc.'s business model. This in-depth Business Model Canvas reveals how the company creates value, navigates a competitive biotech landscape, and positions itself for growth. Ideal for investors, analysts, and strategists seeking actionable insight—get the full canvas to see the complete picture.
Partnerships
Servier allogeneic CAR T alliance
Precision BioSciences, Inc. works with Les Laboratoires Servier on allogeneic CAR T-cell development and commercialization, with programs aimed at multiple antigen targets beyond CD19. The alliance broadens Precision BioSciences, Inc. into hematologic cancers and solid tumors, where allogeneic CAR T is still a small, high-upside field.
Tiziana Life Sciences foralumab study
Precision BioSciences, Inc. collaborates with Tiziana Life Sciences on a foralumab study to assess it as a lymphodepleting agent for next-generation cancer regimens. The tie-up expands Precision BioSciences, Inc.'s immune-modulation toolkit around cell therapy, but publicly disclosed 2025/2026 financial details for this partnership are limited.
iECURE ARCUS gene editing collaboration
Precision BioSciences, Inc. partners with iECURE on ARCUS-based gene editing therapies, extending ARCUS beyond oncology into genetic disease. The deal supports external platform validation and adds to ARCUS’s wider pipeline, which by 2025 had moved into multiple non-oncology programs, strengthening its case as a broader gene-editing engine.
Clinical investigators and trial sites
Precision BioSciences, Inc. relies on hospitals, oncology centers, and investigators to run its Phase 1 and Phase 1/2a studies, where patient enrollment and strict protocol execution drive the first human data. These sites are the main engine for safety, dose, and early efficacy readouts, so trial quality depends on their speed and consistency.
- Run early-stage trials
- Enroll eligible patients
- Execute study protocols
- Generate clinical data
Manufacturing and CMC service partners
Precision BioSciences depends on manufacturing and CMC partners for process development, analytical testing, and GMP supply continuity, so it does not need to build every cell and gene therapy capability in-house. In 2025, this model matters more because CMC work spans 3 critical steps: scale-up, release testing, and batch supply.
- External partners cut fixed cost
- Support faster process scale-up
- Help keep GMP supply flowing
Precision BioSciences Builds Risk-Spreading Partnership Momentum
Precision BioSciences, Inc. leans on three partnership lanes: ARCUS licensing with Les Laboratoires Servier and iECURE, immune-modulation work with Tiziana Life Sciences, and trial and CMC vendors that keep Phase 1 and GMP supply moving. These ties spread risk and help fund a broader 2025/2026 pipeline, while public cash terms stay limited.
| Partner | Role | 2025/2026 note |
|---|---|---|
| Les Laboratoires Servier | Allogeneic CAR T | Multiple targets beyond CD19 |
| Tiziana Life Sciences | Foralumab study | Limited public financial detail |
| iECURE | ARCUS gene editing | Non-oncology platform reach |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas for Precision BioSciences, Inc. covering key segments, partners, and value drivers.
Customizable Excel Spreadsheet
Quickly clarifies Precision BioSciences’ business model and pain points in one editable, board-ready snapshot.
Reference Sources
Provides a credible source trail for Precision BioSciences, Inc., making key claims easy to verify and decisions easier to defend.
Activities
ARCUS genome editing development
Precision BioSciences, Inc. designs and advances the ARCUS genome editing platform, using it as the core engine for both in vivo and ex vivo editing programs. In 2025, this platform remained the main technical asset behind its pipeline, supporting targeted DNA cutting and editing for therapeutic development.
Allogeneic CAR T clinical advancement
Precision BioSciences runs allogeneic CAR T clinical development for off-the-shelf cell therapy, led by PBCAR0191 in Phase 1/2a for relapsed/refractory non-Hodgkin lymphoma and relapsed/refractory B-cell precursor ALL.
PBCAR269A and PBCAR19B extend the portfolio, keeping the focus on scalable, multi-program clinical execution.
Gene-edit design and cell engineering
Precision BioSciences, Inc. uses gene-edit design and cell engineering to make precise edits that improve cell therapy performance. PBCAR19B uses a single-step edit and a stealth cell approach, which helps reduce product risk and support better function in hard-to-treat cancers.
Preclinical and translational research
Precision BioSciences advances ARCUS candidates from discovery into translational studies, where target selection, proof of concept, and IND-enabling work build the case for first-in-human trials. This activity is central to moving assets from lab data into clinical readiness.
- Targets are narrowed early.
- Proof of concept de-risks assets.
- IND packages support trial entry.
Partnering, licensing, and program management
Precision BioSciences runs partnering, licensing, and program management across 3 named collaborations: Servier, Tiziana, and iECURE. It coordinates development plans, milestone tracking, and commercialization rights, so partner cash can fund pipeline work and reduce Company Name’s own R&D burden.
- 3 active collaborations
- Milestone-driven funding
- Shared commercialization rights
Precision BioSciences Advances ARCUS and CAR T With 3 Collaborations
Precision BioSciences, Inc. focuses on ARCUS genome editing, preclinical-to-IND development, and clinical execution of its allogeneic CAR T pipeline. In 2025, it had 3 active collaborations and 3 named CAR T programs, with partner deals helping fund R&D and lower internal spend.
| Metric | 2025 |
|---|---|
| Active collaborations | 3 |
| Named CAR T programs | 3 |
Full Document Unlocks After Purchase
Business Model Canvas
This Precision BioSciences, Inc. Business Model Canvas preview is the exact document you’ll receive after purchase. It’s not a sample or mockup—what you see here is a direct preview of the final file. Once you buy, you’ll get the same fully formatted document, ready to download and use immediately.
Resources
ARCUS proprietary platform
ARCUS is Precision BioSciences, Inc.'s core intellectual property and gene-editing platform, built to enable therapeutic genome editing with high precision. It underpins the company’s pipeline and differentiates Precision BioSciences, Inc. from other biotech firms by giving it a proprietary base for partnerable, disease-targeted programs.
Clinical-stage pipeline assets
Precision BioSciences, Inc. counts three clinical-stage resources in this pillar: PBCAR0191, PBCAR19B, and PBCAR269A. These 3 programs give the company concrete assets for development and partnering, and they are the main near-term drivers of pipeline value.
Scientific and clinical expertise
Precision BioSciences needs specialized talent in gene editing, immunology, and translational medicine to design ARCUS edits, run preclinical tests, and execute clinical trials. In 2025, its clinical pipeline, including PBGENE-HBV, showed why this expertise matters: it protects technical credibility and lowers execution risk.
Partnership rights and collaboration agreements
Strategic agreements with Servier, Tiziana, and iECURE are key resources for Precision BioSciences, Inc. They give the Company outside development paths, shared economics, and more shots at value creation without funding every program alone. In 2025, Precision BioSciences reported $7.8 million in collaboration revenue and ended the year with $118.3 million in cash, cash equivalents, and marketable securities, showing why partnership rights matter.
- Servier, Tiziana, and iECURE expand program reach
- Shared economics lower internal capital needs
- Partnerships add external validation and options
Durham, North Carolina headquarters
Precision BioSciences, Inc.’s Durham, North Carolina headquarters anchors leadership, operations, and coordination in the Research Triangle, a top U.S. biotech hub centered on Duke, UNC, and NC State. The base supports hiring and ecosystem access in a metro area of about 300+ life-sciences employers.
- Central hub for management and execution
- Located in a major biotech cluster
- Supports recruiting and partner access
Precision BioSciences: ARCUS Platform, Clinical Assets, and $118.3M Cash
Precision BioSciences, Inc.’s key resources are ARCUS, its proprietary gene-editing platform, and a focused set of clinical assets: PBGENE-HBV, PBCAR0191, PBCAR19B, and PBCAR269A. These resources are backed by specialized gene-editing talent, partner ties with Servier, Tiziana, and iECURE, and a 2025 year-end cash position of $118.3 million.
| Resource | 2025/2026 data |
|---|---|
| Cash, cash equivalents, marketable securities | $118.3 million |
| Collaboration revenue | $7.8 million |
| Clinical programs | 4 named assets |
Value Propositions
Potentially curative gene editing
Precision BioSciences, Inc. uses ARCUS to make precise genome changes that target the root cause of genetic disease, not just symptoms. That design supports potentially curative therapies and aims for durable outcomes with one-time editing rather than chronic treatment.
Off-the-shelf allogeneic CAR T
Precision BioSciences, Inc. develops off-the-shelf allogeneic CAR T from donor cells, not a patient’s own cells, so treatment can be made in batches and shipped faster. That matters because autologous CAR T often takes about 2–4 weeks to make, while a ready-made model can widen access and lower per-patient manufacturing friction.
Multi-target oncology pipeline
Precision BioSciences’ multi-target oncology pipeline spans CD19 and BCMA, plus partnered targets, giving it exposure to at least 2 major hematologic malignancy markets. This breadth helps reduce single-asset risk and gives the Company more shots at clinical and commercial value.
Stealth cell engineering
Precision BioSciences, Inc. uses PBCAR19B with a single-step gene edit to create a stealth cell profile, aiming to cut chromosomal abnormalities and support safer, easier-to-make cell therapies. That matters because cleaner genome editing can improve both product quality and manufacturing consistency.
- Single-step edit
- Stealth cell profile
- Lower chromosomal risk
- Better safety and manufacturability
Dual platform strategy
Precision BioSciences, Inc. uses a dual platform strategy across in vivo gene editing and ex vivo cell therapy, so it can target two distinct therapeutic paths with one ARCUS nuclease platform. That broadens the addressable market beyond a single modality and opens more partnering and licensing routes, from one-off programs to multi-asset deals.
- In vivo and ex vivo coverage
- Broader market reach
- More partnering options
Precision BioSciences’ ARCUS: Two Modalities, One Platform
Precision BioSciences, Inc. sells ARCUS as one platform for two paths: in vivo gene editing and off-the-shelf allogeneic CAR T. The pitch is precision editing, faster batch-made cell therapy, and broader shots at value across 2 core oncology targets, CD19 and BCMA.
| Value driver | Data point |
|---|---|
| Platform | ARCUS |
| Modalities | 2 |
| Core targets | CD19, BCMA |
Customer Relationships
Strategic co-development agreements
Precision BioSciences uses strategic co-development agreements to lock in long-term partner ties, with formal contracts that split development work and economics across programs. This partner-led model sits at the center of the business, helping Precision share risk, keep R&D spending focused, and advance platform assets with collaborators.
Clinical trial site engagement
Precision BioSciences, Inc. works closely with investigators and hospitals to enroll patients and keep clinical sites running on time. These ties support trial execution, clean data capture, and protocol adherence, which matter most in clinical-stage development.
For a gene-editing biotech with limited patient pools, even small site delays can slow readouts and raise costs, so strong site engagement is a core operating need.
Scientific exchange with partners
Precision BioSciences keeps active technical exchange with partners to align target selection, study design, and translational plans. This tight loop helps speed go/no-go decisions across programs and supports its 2025–2026 collaboration-driven pipeline work.
Regulatory and quality coordination
Precision BioSciences must keep tight, documented contact with regulators and quality teams because each IND, amendment, and clinical step can trigger review. In 2025, that matters even more for a small clinical-stage company with limited cash runway and high execution risk, so structured coordination helps avoid delays and costly trial resets.
- Frequent regulator check-ins
- Fast IND and amendment handling
- Quality review before submissions
- Lower clinical execution risk
Investors and capital market communication
Precision BioSciences keeps active contact with investors and analysts through earnings calls and SEC filings, because public biotech funding depends on trust and clear updates. That link matters: gene-editing R&D is capital-heavy, so good investor communication helps support follow-on financing and visibility.
- Regular updates build trust
- Helps fund costly R&D
- Improves analyst visibility
Precision BioSciences’ 2025 Make-or-Break Customer Links
Precision BioSciences, Inc. relies on a few high-touch customer links: co-development partners, clinical sites, regulators, and investors. That mix matters in 2025 because one delayed site or filing can slow its gene-editing readouts and burn cash fast.
| Customer relationship | 2025 focus | Value |
|---|---|---|
| Partners | Co-development | Risk sharing |
| Sites | Trial execution | Faster enrollment |
| Investors | SEC updates | Funding access |
Channels
Clinical trial network
Precision BioSciences reaches patients through clinical trial sites that run its studies, and this channel is the main way it validates programs and gathers real-world safety and efficacy data. In 2025, its clinical pipeline included PBGENE-HBV and PBGENE-3243 in early-stage human studies, so each site feed directly into program readouts and next-step decisions.
Partner commercial organizations
Servier is a key external commercialization channel for Precision BioSciences, Inc.’s partnered programs, giving them global market access that Precision’s small internal team cannot match. This matters for future launches because Servier’s established oncology footprint can speed payer, regulatory, and physician reach across multiple countries.
Biopharma collaboration channels
Precision BioSciences, Inc. uses biopharma collaboration channels to market ARCUS and cell therapy through partnership talks with other life science firms, which supports licensing and co-development deals. In 2025, this model mattered because the company still relied on partnered programs rather than product sales to monetize its platform.
Scientific and medical conferences
Precision BioSciences uses scientific and medical conferences to present platform data, recent study updates, and trial progress, which builds credibility with investors and key opinion leaders. These events also support business development by helping the Company meet collaborators and investigators who can move programs forward.
At major meetings like ASGCT, AACR, and ASH, one strong dataset can drive new partnering talks and expand trial networks faster than direct outreach alone.
- Shares data and platform progress
- Builds credibility with peers
- Attracts collaborators and investigators
Corporate and investor communications
Precision BioSciences, Inc. uses public filings, press releases, and investor materials to keep the market updated on pipeline and partnership progress. These three channels help shape capital formation and market awareness by giving investors timely, SEC-grade updates on clinical and business milestones.
Public filings: formal, regulated updates
Press releases: pipeline and deal news
Investor materials: clearer story for capital
Precision BioSciences Uses Trials, Partners, and Conferences to Drive Deals
Precision BioSciences, Inc. relies on clinical trial sites, partnership channels, and scientific meetings to move ARCUS and cell therapy data into readouts and deals. In 2025, PBGENE-HBV and PBGENE-3243 were in early human studies, while Servier remained a key route to global reach for partnered programs.
| Channel | Role | 2025 signal |
|---|---|---|
| Clinical sites | Trial execution | Early human studies |
| Servier | Commercial access | Global reach |
| Conferences | Data sharing | ASGCT, AACR, ASH |
Customer Segments
Patients with R/R B-cell malignancies
The first clinical demand segment for Precision BioSciences, Inc. is adults with relapsed or refractory non-Hodgkin lymphoma and B-cell precursor ALL, the patient group targeted by PBCAR0191. This is a high-need, first-line for adoption segment because relapse after standard therapy leaves few durable options and drives trial demand.
Patients with R/R multiple myeloma
Patients with relapsed/refractory multiple myeloma are a major target group for Precision BioSciences, Inc. PBCAR269A is an allogeneic CAR T candidate aimed at BCMA, a key myeloma marker, and it broadens the company beyond CD19; multiple myeloma caused about 35,000 new U.S. cases in 2024 and remains largely incurable after relapse.
Biopharma licensing partners
Biopharma licensing partners are pharmaceutical and biotechnology companies that use Precision BioSciences, Inc. gene editing and cell therapy platforms through licenses or co-development deals. This is a core revenue-facing segment, and in 2025 Precision BioSciences kept building partner-led value through its ARCUS-based programs and externally funded development work.
Academic and clinical research institutions
Hospitals, cancer centers, and academic investigators are key customers for Precision BioSciences, Inc. because they run trials, translational studies, and publish the data that supports clinical use. These institutions also help validate the ARCUS platform scientifically and widen adoption across research networks.
- Run trials and translational studies
- Use Precision BioSciences, Inc. clinical data
- Help validate the platform
Genetic disease therapy developers
Genetic disease therapy developers, including companies like iECURE, are a key customer segment for Precision BioSciences, Inc. They need site-specific gene editing for inherited diseases, and ARCUS fits that need by supporting durable, targeted edits for partnership-led programs.
- Focus: inherited disease gene editing
- Value driver: ARCUS platform fit
- Monetization: partnerships and licensing
For these developers, Precision BioSciences, Inc. can turn platform access into upfront fees, milestones, and royalties.
Precision BioSciences Targets Patients, Partners, and Trial Sites
Precision BioSciences, Inc. serves two main customer groups: high-need cancer patients in trials for relapsed or refractory NHL, B-ALL, and multiple myeloma, and biopharma partners that license ARCUS for gene editing and cell therapy. It also sells into hospitals and academic centers that run studies and validate the platform.
| Customer segment | Role | 2025/2026 signal |
|---|---|---|
| Patients | Trial demand | 3 oncology programs |
| Biopharma | Licensing | Upfront, milestones, royalties |
| Hospitals | Clinical validation | Trial sites and data |
Cost Structure
Research and development expense
In fiscal 2025, Precision BioSciences, Inc. kept research and development as its main cost line, driven by ARCUS gene-editing design, assay work, and translational research. That spend is what keeps the pipeline moving, because each program needs repeated discovery and validation before it can advance.
Clinical trial costs
Clinical trial costs are a major fixed cost for Precision BioSciences, Inc., because Phase 1 and Phase 1/2a studies need trial sites, monitoring, data management, and patient support. In cell and gene therapy, these costs are especially high and usually climb as programs move from early safety work into larger, more complex trials.
Manufacturing and CMC spending
Precision BioSciences' cell-therapy CMC work is a major cost line: process development, analytics, testing, product release, materials, and supply-chain readiness all need spending before a batch can ship. In 2025, that kind of work sat inside a tight cash-burn model, so each added program raises operating cost and slows scale-up if release-ready manufacturing slips.
General and administrative overhead
Precision BioSciences, Inc. carries public-company G&A costs tied to leadership, legal, finance, and HR, plus Nasdaq reporting and compliance. For a listed biotech, these are fixed corporate costs that keep the platform running while it funds R&D; in 2024, G&A was a material part of operating spend alongside research programs.
- Leadership and board costs
- Legal, audit, and SEC reporting
- Finance, HR, and payroll support
- Public-company compliance overhead
Partnering and regulatory costs
Precision BioSciences, Inc. bears steady partnering and regulatory costs because business development, contract work, and agency meetings all need staff time, legal review, and quality systems. In 2025, those fixed controls stayed essential for collaboration terms, IND support, and approval-ready documentation.
- Business development drives legal spend
- Regulatory work needs full documentation
- Quality systems support partner approvals
Precision BioSciences' 2025 spending was led by R&D, not scale manufacturing
In fiscal 2025, Precision BioSciences, Inc. spent most on research and development, with clinical and CMC work driving the burn; R&D was $36.6 million versus G&A at $13.2 million. That mix shows a cost base still centered on ARCUS pipeline progress, not scale manufacturing.
| 2025 cost line | Amount |
|---|---|
| Research and development | $36.6 million |
| General and administrative | $13.2 million |
Revenue Streams
Collaborative milestone payments
Precision BioSciences, Inc. can earn collaborative milestone payments tied to research, development, and commercialization steps, a common biotech deal structure that brings non-dilutive cash as programs advance. In 2025, its partnership model still relied on these progress-linked receipts, so each signed program can add cash without issuing new shares.
Upfront collaboration fees
Upfront collaboration fees give Precision BioSciences, Inc. cash at signing, so revenue starts before any product sale. In 2025, these early payments were a key source of non-dilutive funding for ongoing ARCUS development and helped support R&D spending while the company advanced its pipeline.
Royalties on future sales
Precision BioSciences, Inc. can earn royalties if partnered drugs, including Servier-related programs, reach the market, turning today’s deal flow into future sales income. That upside matters because the company currently has no marketed products, so royalty checks would be long-dated but potentially high-margin.
License and option revenue
Precision BioSciences, Inc. can turn ARCUS into license fees, option payments, milestones, and future royalties, so one asset can serve several external partners. In FY2025, this kind of deal flow helped broaden revenue beyond product sales and lower dependence on any single program.
- Upfront cash from access deals
- Milestones tied to progress
- Royalties on partner sales
Research and development collaboration funding
Precision BioSciences, Inc. can receive research and development collaboration funding when partners pay for joint work, including the iECURE program. This kind of funding helps offset internal R&D spend and extends runway; as of March 31, 2025, Precision BioSciences, Inc. reported $78.6 million in cash, cash equivalents, and marketable securities.
- Partner-funded joint development work
- Supports iECURE and other collaborations
- Lowers internal R&D cash burn
- Helps preserve runway into 2025
Precision BioSciences: Partnership-Driven Revenue, Not Product Sales
Precision BioSciences, Inc. revenue comes mainly from collaboration fees, research funding, milestone payments, and future royalties, not product sales. In FY2025, this model kept cash coming in from ARCUS partnerships and iECURE work, while the company held $78.6 million in cash, cash equivalents, and marketable securities at March 31, 2025.
| Stream | 2025 role |
|---|---|
| Upfront fees | Cash at signing |
| Milestones | Progress-linked receipts |
| Royalties | Future partner sales income |
| R&D funding | Offsets internal spend |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.